Refractory Chronic Migraine
Conditions
Brief summary
Treatment of chronic migraineurs who have failed more than 3 preventive drugs with Erenumab alone, to reduce frequency of monthly migraine days or as an add on therapy
Detailed description
The investigators treated chronic migraineurs that have failed more than 3 preventive drugs with Erenumab alone or as an add on therapy to: Reduce the frequency of monthly migraine days, to evaluate If the add on of Erenumab to another preventive therapy is superior to Erenumab alone, and assess all adverse events related to the use of Erenumab. Migraineurs with 15-30 migraie days per month at baseline were clustered in 3 categories. Failure of Erenumab was defined as no improvement in the frequency of monthly migraine days. Group I: no preventive therapy, prior to the start of Erenumab. (No botox cohort). Group II: on Botulinum Toxin A (Botox), prior to the add on therapy with Erenumab. (Botox cohort).Group III: on an oral preventive drug, prior to the add on therapy with Erenumab. (No Botox cohort)
Interventions
DRUGErenumab Auto-Injector
Assess synergy of add on medication to Erenumab
Sponsors
Clinique des Céphalées de Montréal
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* chronic migraineurs with failure to more than 3 preventive treatments * Naive to anti CGRP monclonal antibodies
Exclusion criteria
* episodic migraineurs, * Other headache types
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in monthly migraine days | 5 months | Change in frequency of monthly migraine days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in frequency of monthly migraine days adding Erenumab to another preventive treatment, | 5 months | Change in the frequency of monthly migraine days with Botox plus Erenumab, |
| Change in the frequency of monthly migraine days adding Erenumab to another preventive treatment | 5 months | Change in the freqyency of monthly migraine days with an oral preventive plu erenumab |
| change in frequency of monthly migraine days with Erenumab alone | 5 months | change in frequency of monthly migraine days without adding another preventive to Erenumab |
Countries
Canada
Outcome results
None listed